Triple-negative breast cancer claims most of its lives not at the site of origin, but in the distant organs where escaped cells quietly wait to reawaken. Researchers in Adelaide and Melbourne have traced one mechanism of that reawakening to the loss of a small molecular regulator called miR-342, whose absence frees a cell-cycle pathway to drive metastatic growth. In doing so, they have identified a biological signature that may allow clinicians to match a subset of TNBC patients to a drug class already proven in other breast cancers — not to defeat the primary tumor, but to hold the metastatic
miR-342 Loss Drives TNBC Metastasis; CDK4/6 Inhibitors Show Promise in Preclinical Models
Triple-negative breast cancer remains a leading cause of breast cancer mortality, particularly when disease spreads to distant organs; this research targets the metastatic progression that accounts for most TNBC deaths.